AU2001250404A1 - Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system - Google Patents

Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system

Info

Publication number
AU2001250404A1
AU2001250404A1 AU2001250404A AU5040401A AU2001250404A1 AU 2001250404 A1 AU2001250404 A1 AU 2001250404A1 AU 2001250404 A AU2001250404 A AU 2001250404A AU 5040401 A AU5040401 A AU 5040401A AU 2001250404 A1 AU2001250404 A1 AU 2001250404A1
Authority
AU
Australia
Prior art keywords
treatment
nervous system
central nervous
dopamine
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001250404A
Inventor
Gerhard Gross
Dorothea Starck
Hans-Jurgen Teschendorf
Hans Jorg Treiber
Liliane Unger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of AU2001250404A1 publication Critical patent/AU2001250404A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of at least one compound of the general formula I, L-D-B-G (I) in which L and G are aromatic, optionally heterocyclic radicals, D is an aliphatic or heteroaliphatic connecting link and B is a 6-, 7- or 8-membered saturated or unsaturated ring bonded to D via the 1 position and to G via the 4 or 5 position and having one or two nitrogen heteroatoms, for the treatment of disorders of the central nervous system and in particular of disorders which are to be assigned to the psychiatric or neurological type. These compounds offer particular advantages in the control of addiction.
AU2001250404A 2000-03-27 2001-03-26 Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system Abandoned AU2001250404A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10015211 2000-03-27
DE10015211 2000-03-27
PCT/EP2001/003411 WO2001072306A1 (en) 2000-03-27 2001-03-26 Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system

Publications (1)

Publication Number Publication Date
AU2001250404A1 true AU2001250404A1 (en) 2001-10-08

Family

ID=7636586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001250404A Abandoned AU2001250404A1 (en) 2000-03-27 2001-03-26 Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system

Country Status (7)

Country Link
US (1) US20030087917A1 (en)
EP (1) EP1272187B1 (en)
AT (1) ATE402704T1 (en)
AU (1) AU2001250404A1 (en)
DE (1) DE50114170D1 (en)
ES (1) ES2311012T3 (en)
WO (1) WO2001072306A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10109867A1 (en) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Use of triazole compounds for the prophylaxis and therapy of neurodegenerative diseases, brain trauma and cerebral ischemia
DE10109866A1 (en) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazole compounds and their use for the prophylaxis and therapy of neurodegenerative diseases, brain trauma and cerebral ischemia
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
KR101255356B1 (en) 2002-06-12 2013-04-17 케모센트릭스, 인크. 1-aryl-4-substituted piperazines derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
EA009480B1 (en) 2003-07-24 2008-02-28 Еуро-Селтик С. А. Heteroaryl-tetrahydropiperidyl compounds useful for treating or prevention pain
JP4845873B2 (en) * 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US8389549B2 (en) * 2007-04-27 2013-03-05 Purdue Pharma L.P. Substituted pyridines useful for treating pain
PL3562822T3 (en) 2016-12-30 2021-09-13 Mitobridge, Inc. Poly-adp ribose polymerase (parp) inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119758A1 (en) * 1991-06-15 1992-12-17 Basf Ag AMINOALKYL-SUBSTITUTED 2-AMINO-5-MERCAPTOTHIADIAZOLE, THEIR PRODUCTION AND USE
US5395835A (en) * 1994-03-24 1995-03-07 Warner-Lambert Company Naphthalamides as central nervous system agents
DE4425145A1 (en) * 1994-07-15 1996-01-18 Basf Ag Use of thiazole and thiadiazole compounds
DE4425144A1 (en) * 1994-07-15 1996-01-18 Basf Ag Triazole compounds and their use
DE4425146A1 (en) * 1994-07-15 1996-01-18 Basf Ag Use of heterocyclic compounds
DE4425143A1 (en) * 1994-07-15 1996-01-18 Basf Ag Substituted pyrimidine compounds and their use
FR2742149B1 (en) * 1995-12-11 1998-02-13 Inst Nat Sante Rech Med NOVEL 2-NAPHTAMIDE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
DE19600934A1 (en) * 1996-01-12 1997-07-17 Basf Ag Substituted aza and diazacycloheptane and cyclooctane compounds and their use
DE19728996A1 (en) * 1997-07-07 1999-01-14 Basf Ag Triazole compounds and their use
DE19735410A1 (en) * 1997-08-14 1999-02-18 Basf Ag New stable fumarate salt of pyrimidinol derivative dopamine D3 receptor ligand, having improved solubility and suitable for oral administration
AU783786B2 (en) * 1999-12-30 2005-12-08 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives

Also Published As

Publication number Publication date
DE50114170D1 (en) 2008-09-11
EP1272187B1 (en) 2008-07-30
ATE402704T1 (en) 2008-08-15
US20030087917A1 (en) 2003-05-08
ES2311012T3 (en) 2009-02-01
EP1272187A1 (en) 2003-01-08
WO2001072306A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
IL127244A0 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
EP1458708A4 (en) Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
YU63202A (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
UA66825C2 (en) Azapolycyclic compounds condensed with aryl
TW200500344A (en) Novel compounds
GR3029853T3 (en) Diazabicyclic neurokinin antagonists
AU2001250404A1 (en) Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
BG106509A (en) Preparative form
MY124786A (en) Bis-arylsulfones
GB9923077D0 (en) Sapogenin derivatives and their use
MY129130A (en) (+)-norcisapride
CA2244777A1 (en) 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
ATE325610T1 (en) XANTHINE DERIVATIVES FOR THE TREATMENT OF BRAIN SCHEMIA
BG103687A (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
MXPA04003544A (en) Benzotriazepines as gastrin and cholecystokinin receptor ligands.
HUP0100611A2 (en) Triazine compounds for treatment of cns disorders
BG102707A (en) New triazolopurinpurines, method for their preparation and appplication as medicamentous forms
BG108164A (en) Glyt-1 inhibitors
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
PT889044E (en) DERIVATIVES OF 5- (HETEROARIL) ALTAL-3-OXO-PYRID- (1,2-A) BENZIMIDAZOLE-4-CARBOXAMIDE (GDP) USEFUL IN TREATING PERTURBACTIONS OF THE CENTRAL NERVOUS SYSTEM
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system